[Treatment of chronic urticaria with astemizole: a multicenter pediatric study].
An open multicentric pediatric clinical trial has been performed to evaluate the safety and efficacy of astemizole (HISMANAL suspension) at a 1 ml (2 mg) dosage per 10 kg body weight once daily in children with chronic urticaria. A good and very good effect has been observed in 63.2% of the children at day 7, in 79.2% after 2 weeks and in 88.9% at the end of the treatment (4 weeks). A marked improvement of the symptoms was reported in 63.8% of children at day 7. There was no decrease of efficacy at the end of the treatment. Tolerance was good in 87.% of the cases. Astemizole seems to be a useful treatment for chronic urticaria in pediatrics.
D000293:Adolescent; D016589:Astemizole; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D014581:Urticaria / Q000188:drug therapy* / Q000276:immunology
D001562:Benzimidazoles; D016589:Astemizole
Traitement de l'urticaire chronique par l'astémizole: étude multicentrique pédiatrique.